Protalix BioTherapeutics ... (PLX)
AMEX: PLX
· Real-Time Price · USD
1.48
-0.04 (-2.63%)
At close: Aug 15, 2025, 3:59 PM
1.50
1.35%
After-hours: Aug 15, 2025, 05:59 PM EDT
Protalix BioTherapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | 3.91M | 2.93M | -9.61M | -14.69M | 6.85M | 8.31M | 10.62M | 8.9M | -15.77M | -14.93M | -17.85M | -18.49M | -24.39M | -27.58M | -20.52M | -20.76M | -13.66M |
Depreciation & Amortization | 1.33M | 1.3M | 1.28M | 1.26M | 1.23M | 1.19M | 1.15M | 1.12M | 1.1M | 1.09M | 1.07M | 1.08M | 1.1M | 1.12M | 1.15M | 1.17M | 1.21M |
Stock-Based Compensation | 2.81M | 3.25M | 3.97M | 4.44M | 3.88M | 3.45M | 2.62M | 1.95M | 1.79M | 2.08M | 1.96M | 2.1M | 2.4M | 2.38M | 2.97M | 3.82M | 3.51M |
Other Working Capital | -15.33M | -4.26M | -4.24M | 12.72M | -736K | -13.17M | -10.32M | -13.26M | -1.46M | -2.73M | -6.29M | -1.69M | 14.28M | 13.25M | 2.82M | -3.08M | -22.71M |
Other Non-Cash Items | 4.49M | 4.4M | 1.53M | -4.28M | -4.19M | -3.72M | -797K | -395K | -1.18M | -1.23M | -841K | 44K | 2.27M | 3.09M | 4.06M | 4.03M | 3.84M |
Deferred Income Tax | 261K | 236K | 3.33M | 2.92M | -149K | -11K | -3.1M | -3.14M | n/a | n/a | 8K | 850K | 836K | 813K | 782K | -688K | -648K |
Change in Working Capital | -13.37M | -3.45M | 7.77M | 7.64M | -1.75M | -10.54M | -18.01M | -18.27M | -8.11M | -12.02M | -11.82M | -5.75M | 11.51M | 9.9M | -1.2M | -2.05M | -23.07M |
Operating Cash Flow | -572K | 8.67M | 8.28M | -2.71M | 5.87M | -1.32M | -7.52M | -9.84M | -22.17M | -25M | -27.48M | -20.15M | -6.28M | -10.29M | -12.75M | -14.47M | -28.82M |
Capital Expenditures | -990K | -1.28M | -1.11M | -1.47M | -1.5M | -1.15M | -1.11M | -723K | -647K | -628K | -863K | -1.15M | -1.3M | -1.46M | -1.29M | -1.04M | -975K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -37.84M | -37.84M | -37.84M | -37.78M | 53K | 53K | 53K |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | 16M | 16M | 16M | n/a | 21.84M | 21.84M | 21.84M | n/a | -30.34M | -22.84M | -22.84M |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | 5M | 10M | 16M | 16M | 11M | 43.84M | 42.84M | 50.34M | 57.84M | 20M | 15M | 7.5M |
Other Investing Acitivies | 5.5M | 5.5M | 20.31M | -20.54M | -20.55M | -20.56M | -36.3M | -15.9M | -15.4M | -15.41M | 476K | 479K | 315K | 327K | 645K | 1.08M | 700K |
Investing Cash Flow | 4.51M | 4.22M | 19.2M | -22.01M | -22.05M | -16.71M | -11.42M | 15.38M | 15.95M | -5.04M | 27.45M | 26.16M | 33.35M | 18.92M | -10.92M | -7.75M | -15.56M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 40K | -25.95M | -25.95M | -30.04M | -30.08M | -4.09M | -4.09M |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -18.2M | -20.42M | -20.42M | n/a | 712K | 712K | 712K | 712K | 2.64M | 2.64M | -1.44M | -1.44M | -4.09M | 42.11M | 45.98M | 46.46M | 46.46M |
Financial Cash Flow | -11.72M | -16.79M | -20.42M | n/a | 10.43M | 24.67M | 28.74M | 30.26M | 22.47M | 8.24M | 117K | -27.39M | -30.04M | 12.08M | 20.78M | 51.24M | 49.97M |
Net Cash Flow | -7.75M | -3.87M | 7M | -24.79M | -5.83M | 6.52M | 9.69M | 35.69M | 16.15M | -21.87M | 78K | -21.39M | -2.94M | 20.72M | -2.89M | 29.04M | 5.66M |
Free Cash Flow | -1.56M | 7.39M | 7.17M | -4.18M | 4.37M | -2.47M | -8.64M | -10.56M | -22.82M | -25.63M | -28.34M | -21.3M | -7.58M | -11.74M | -14.03M | -15.52M | -29.8M |